BMS-986251 is a potent and specific RORgammat inverse agonist that exerts its action via oral administration. It shows an EC 50 of 12 nM for RORgammat GAL4. In human whole blood assay, BMS-986251 effectively inhibits IL-17 with an EC 50 of 24 nM. Furthermore, BMS-986251 exhibits strong therapeutic effects in mouse acanthosis and Imiquimod-induced models, which are commonly used preclinical models for psoriasis.